Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine.

Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE.

Arch Gen Psychiatry. 2002 May;59(5):409-16.

PMID:
11982444
2.

Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe.

Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE.

Arch Gen Psychiatry. 2005 Nov;62(11):1228-36.

PMID:
16275810
3.

Brain reward system activity in major depression and comorbid nicotine dependence.

Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE.

J Pharmacol Exp Ther. 2002 Sep;302(3):1265-71.

4.

[Personality factors in depressive disorders: contribution of the psychobiologic model developed by Cloninger].

Pelissolo A, Corruble E.

Encephale. 2002 Jul-Aug;28(4):363-73. Review. French.

PMID:
12232546
5.
6.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
7.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
8.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM.

J Clin Psychiatry. 2004 Apr;65(4):521-30.

PMID:
15119915
9.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
10.

Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.

Khan A, Brodhead AE, Kolts RL, Brown WA.

J Psychiatr Res. 2005 Mar;39(2):145-50.

PMID:
15589562
11.
12.
13.

The role of the brain reward system in depression.

Naranjo CA, Tremblay LK, Busto UE.

Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):781-823. Review.

PMID:
11383978
14.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
15.

Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR.

Arch Gen Psychiatry. 2005 Feb;62(2):154-62.

PMID:
15699292
16.
17.

Relationship between borderline personality disorder and Axis I diagnosis in severity of depression and anxiety.

Comtois KA, Cowley DS, Dunner DL, Roy-Byrne PP.

J Clin Psychiatry. 1999 Nov;60(11):752-8.

PMID:
10584763
18.

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Burke WJ, Gergel I, Bose A.

J Clin Psychiatry. 2002 Apr;63(4):331-6.

PMID:
12000207
19.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
Items per page

Supplemental Content

Write to the Help Desk